The quality of economic evaluations of ultra-orphan drugs in Europe – a systematic review
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1172
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The quality of economic evaluations of ultra-orphan drugs in Europe – a systematic review ; volume:10 ; number:1 ; day:30 ; month:7 ; year:2015 ; pages:1-12 ; date:12.2015
Orphanet journal of rare diseases ; 10, Heft 1 (30.7.2015), 1-12, 12.2015
- Urheber
-
Schuller, Y.
Hollak, C. E. M.
Biegstraaten, M.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13023-015-0305-y
- URN
-
urn:nbn:de:101:1-2021090119573913566680
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.20252025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Schuller, Y.
- Hollak, C. E. M.
- Biegstraaten, M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs
Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes
Predictors of orphan drug approval
Markenführung Orphan Drugs
Estimating the clinical cost of drug development for orphan versus non-orphan drugs
Developing a Patient-Directed Policy Framework for Managing Orphan and Ultra-Orphan Drugs Throughout Their Lifecycle
Drugs : evaluations of drugs and drug therapy
Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review
Mechanism of coordinated access to orphan drugs
Impact of orphan drugs on Latvian budget
The actual status of drug prices and adjustment factors for drug price calculation: an analysis of ultra-orphan drug development in Japan
Evidenz zu Orphan Drugs : Arbeitspapier
Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs
Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes
Predictors of orphan drug approval
Markenführung Orphan Drugs
Estimating the clinical cost of drug development for orphan versus non-orphan drugs
Developing a Patient-Directed Policy Framework for Managing Orphan and Ultra-Orphan Drugs Throughout Their Lifecycle
Drugs : evaluations of drugs and drug therapy
Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review
Mechanism of coordinated access to orphan drugs
Impact of orphan drugs on Latvian budget
The actual status of drug prices and adjustment factors for drug price calculation: an analysis of ultra-orphan drug development in Japan
Evidenz zu Orphan Drugs : Arbeitspapier
Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs
Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes
Predictors of orphan drug approval
Markenführung Orphan Drugs
Estimating the clinical cost of drug development for orphan versus non-orphan drugs
Developing a Patient-Directed Policy Framework for Managing Orphan and Ultra-Orphan Drugs Throughout Their Lifecycle
Drugs : evaluations of drugs and drug therapy
Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review
Mechanism of coordinated access to orphan drugs
Impact of orphan drugs on Latvian budget
The actual status of drug prices and adjustment factors for drug price calculation: an analysis of ultra-orphan drug development in Japan